The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential
出版年份 2019 全文链接
标题
The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential
作者
关键词
Residual cardiovascular risk, Visceral obesity, Diabetes, Atherogenic dyslipidemia, Triglycerides, Remnant cholesterol, Selective peroxisome proliferator-activated receptor alpha modulator, SPPARMalpha, Pemafibrate (K-877), Inflammation, PROMINENT
出版物
Cardiovascular Diabetology
Volume 18, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2019-06-04
DOI
10.1186/s12933-019-0864-7
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Long-Term Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor-α Modulator (SPPARMα), in Dyslipidemic Patients with Renal Impairment
- (2019) Koutaro Yokote et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Does nonalcoholic fatty liver disease cause cardiovascular disease? Current knowledge and gaps
- (2019) Raul D. Santos et al. ATHEROSCLEROSIS
- Long-term Pemafibrate Treatment Was Well Tolerated in Patients with Dyslipidemia Including Those with Kidney Dysfunction
- (2018) Koutaro Yokote et al. ATHEROSCLEROSIS SUPPLEMENTS
- Molecular association model of PPARα and its new specific and efficient ligand, pemafibrate: Structural basis for SPPARMα
- (2018) Yuta Yamamoto et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the Treating to New Targets (TNT) Trial
- (2018) Antonio J. Vallejo-Vaz et al. CIRCULATION
- Conceptual Framework for Addressing Residual Atherosclerotic Cardiovascular Disease Risk in the Era of Precision Medicine
- (2018) Kershaw V. Patel et al. CIRCULATION
- Tofogliflozin and Pemafibrate Combination Therapy Prevents Nonalcoholic Steatohepatitis (NASH) Development of Novel Metabolic Syndrome–Related NASH Model Mice
- (2018) YUSUKE SASAKI et al. DIABETES
- Effects of Pemafibrate, a Novel Selective PPARα Modulator, on Lipid and Glucose Metabolism in Patients With Type 2 Diabetes and Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial
- (2018) Eiichi Araki et al. DIABETES CARE
- Molecular actions of PPARα in lipid metabolism and inflammation
- (2018) Nadia Bougarne et al. ENDOCRINE REVIEWS
- Association of fatty liver index with the risk of incident cardiovascular disease and acute myocardial infarction
- (2018) Olubunmi O. Olubamwo et al. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
- Peroxisome proliferator-activated receptor alpha-mediated drug toxicity in the liver
- (2018) Maka S. Hedrington et al. Expert Opinion on Drug Metabolism & Toxicology
- A Novel Selective PPARα Modulator (SPPARMα), K-877 (Pemafibrate), Attenuates Postprandial Hypertriglyceridemia in Mice
- (2018) Masami Sairyo et al. Journal of Atherosclerosis and Thrombosis
- Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial
- (2018) Hidenori Arai et al. Journal of Atherosclerosis and Thrombosis
- Nonalcoholic Steatohepatitis is the Most Rapidly Increasing Indication for Liver Transplantation in Young Adults in the United States
- (2018) Iliana Doycheva et al. JOURNAL OF CLINICAL GASTROENTEROLOGY
- Effects of pemafibrate (K-877) on cholesterol efflux capacity and postprandial hyperlipidemia in patients with atherogenic dyslipidemia
- (2018) Shizuya Yamashita et al. Journal of Clinical Lipidology
- Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial
- (2018) Shun Ishibashi et al. Journal of Clinical Lipidology
- Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial
- (2018) Sonia S Anand et al. LANCET
- Overview of Epidemiology and Contribution of Obesity and Body Fat Distribution to Cardiovascular Disease: An Update
- (2018) Marie-Eve Piché et al. PROGRESS IN CARDIOVASCULAR DISEASES
- Effects of a novel selective peroxisome proliferator-activated receptor-α modulator, pemafibrate, on hepatic and peripheral glucose uptake in patients with hypertriglyceridemia and insulin resistance
- (2018) Ikuro Matsuba et al. Journal of Diabetes Investigation
- Diverse Roles of Mitochondria in Immune Responses: Novel Insights Into Immuno-Metabolism
- (2018) Anusha Angajala et al. Frontiers in Immunology
- Associations of Omega-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks
- (2018) Theingi Aung et al. JAMA Cardiology
- Increased Residual Cardiovascular Risk in Patients with Diabetes and High vs. Normal Triglycerides Despite Statin-Controlled LDL Cholesterol
- (2018) Gregory A. Nichols et al. DIABETES OBESITY & METABOLISM
- The Peroxisome Proliferator-Activated Receptor α (PPARα) Agonist Pemafibrate Protects against Diet-Induced Obesity in Mice
- (2018) Masaya Araki et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Extrahepatic PPARα modulates fatty acid oxidation and attenuates fasting-induced hepatosteatosis in mice
- (2018) Chad N. Brocker et al. JOURNAL OF LIPID RESEARCH
- NCD Countdown 2030: worldwide trends in non-communicable disease mortality and progress towards Sustainable Development Goal target 3.4
- (2018) James E Bennett et al. LANCET
- High Triglycerides Are Associated With Increased Cardiovascular Events, Medical Costs, and Resource Use: A Real‐World Administrative Claims Analysis of Statin‐Treated Patients With High Residual Cardiovascular Risk
- (2018) Peter P. Toth et al. Journal of the American Heart Association
- Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study
- (2018) Aruna D. Pradhan et al. AMERICAN HEART JOURNAL
- Low-Grade Inflammation in the Association Between Mild-to-Moderate Hypertriglyceridemia and Risk of Acute Pancreatitis: A Study of More Than 115000 Individuals from the General Population
- (2018) Signe E. J. Hansen et al. CLINICAL CHEMISTRY
- Hypertriglyceridemia in statin-treated US adults: the National Health and Nutrition Examination Survey
- (2018) Wenjun Fan et al. Journal of Clinical Lipidology
- 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol
- (2018) Scott M. Grundy et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
- (2018) Gregory G. Schwartz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
- (2018) Deepak L. Bhatt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liver fat content, non-alcoholic fatty liver disease, and ischaemic heart disease: Mendelian randomization and meta-analysis of 279 013 individuals
- (2017) Bo Kobberø Lauridsen et al. EUROPEAN HEART JOURNAL
- Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
- (2017) Brian A. Ference et al. EUROPEAN HEART JOURNAL
- Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases
- (2017) Leon A Adams et al. GUT
- Atherogenic Dyslipidemia in Latin America: Prevalence, causes and treatment
- (2017) Carlos I. Ponte-Negretti et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Association of Rare and Common Variation in the Lipoprotein Lipase Gene With Coronary Artery Disease
- (2017) Amit V. Khera et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Effects of K-877, a novel selective PPARα modulator, on small intestine contribute to the amelioration of hyperlipidemia in low-density lipoprotein receptor knockout mice
- (2017) Kenta Takei et al. JOURNAL OF PHARMACOLOGICAL SCIENCES
- ANGPTL3 Deficiency and Protection Against Coronary Artery Disease
- (2017) Nathan O. Stitziel et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Renoprotective effect of a novel selective PPARα modulator K-877 in db/db mice: A role of diacylglycerol-protein kinase C-NAD(P)H oxidase pathway
- (2017) Toshinobu Maki et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Angiopoietin-like 3 in lipoprotein metabolism
- (2017) Sander Kersten Nature Reviews Endocrinology
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
- (2017) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease
- (2017) A. Michael Lincoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
- (2017) Paul M Ridker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial
- (2017) Marc S Sabatine et al. Lancet Diabetes & Endocrinology
- Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes
- (2017) Marshall B. Elam et al. JAMA Cardiology
- Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease
- (2017) Marc P. Bonaca et al. CIRCULATION
- Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis
- (2017) Yasushi Honda et al. Scientific Reports
- Non-HDL Cholesterol and TriglyceridesHighlights
- (2016) Rishi Puri et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- The novel selective PPARα modulator (SPPARMα) pemafibrate improves dyslipidemia, enhances reverse cholesterol transport and decreases inflammation and atherosclerosis
- (2016) Nathalie Hennuyer et al. ATHEROSCLEROSIS
- Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial
- (2016) Shun Ishibashi et al. ATHEROSCLEROSIS
- FGF21 Lowers Plasma Triglycerides by Accelerating Lipoprotein Catabolism in White and Brown Adipose Tissues
- (2016) Christian Schlein et al. Cell Metabolism
- Elevated Triglyceride Level Is Independently Associated With Increased All-Cause Mortality in Patients With Established Coronary Heart Disease
- (2016) Robert Klempfner et al.
- Increased Remnant Cholesterol Explains Part of Residual Risk of All-Cause Mortality in 5414 Patients with Ischemic Heart Disease
- (2016) A.-M. K. Jepsen et al. CLINICAL CHEMISTRY
- Why Is Apolipoprotein CIII Emerging as a Novel Therapeutic Target to Reduce the Burden of Cardiovascular Disease?
- (2016) Marja-Riitta Taskinen et al. Current Atherosclerosis Reports
- Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points—a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine
- (2016) Børge G. Nordestgaard et al. EUROPEAN HEART JOURNAL
- 2016 European Guidelines on cardiovascular disease prevention in clinical practice
- (2016) Massimo F. Piepoli et al. EUROPEAN HEART JOURNAL
- 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
- (2016) Alberico L. Catapano et al. EUROPEAN HEART JOURNAL
- Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes
- (2016) Zobair M. Younossi et al. HEPATOLOGY
- Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease
- (2016) NEW ENGLAND JOURNAL OF MEDICINE
- Inactivating Variants in ANGPTL4 and Risk of Coronary Artery Disease
- (2016) Frederick E. Dewey et al. NEW ENGLAND JOURNAL OF MEDICINE
- Elevated Triglyceride Level Is Independently Associated With Increased All-Cause Mortality in Patients With Established Coronary Heart Disease
- (2016) Robert Klempfner et al. Circulation-Cardiovascular Quality and Outcomes
- Kinetic and Related Determinants of Plasma Triglyceride Concentration in Abdominal ObesitySignificance
- (2015) Jan Borén et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Extreme Nonfasting Remnant Cholesterol vs Extreme LDL Cholesterol as Contributors to Cardiovascular Disease and All-Cause Mortality in 90000 Individuals from the General Population
- (2015) A. Varbo et al. CLINICAL CHEMISTRY
- Acetyl-CoA and the regulation of metabolism: mechanisms and consequences
- (2015) Lei Shi et al. CURRENT OPINION IN CELL BIOLOGY
- Metabolic roles of PGC-1α and its implications for type 2 diabetes
- (2015) A. Besseiche et al. DIABETES & METABOLISM
- AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY – CLINICAL PRACTICE GUIDELINES FOR DEVELOPING A DIABETES MELLITUS COMPREHENSIVE CARE PLAN – 2015
- (2015) Yehuda Handelsman et al. Endocrine Practice
- Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective
- (2015) Tomas Jernberg et al. EUROPEAN HEART JOURNAL
- Transcriptome Analysis of K-877 (a Novel Selective PPARα Modulator (SPPARMα))-Regulated Genes in Primary Human Hepatocytes and the Mouse Liver
- (2015) Sana Raza-Iqbal et al. Journal of Atherosclerosis and Thrombosis
- Fasting Triglycerides Predict Recurrent Ischemic Events in Patients With Acute Coronary Syndrome Treated With Statins
- (2015) Gregory G. Schwartz et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- FGF21 Revolutions: Recent Advances Illuminating FGF21 Biology and Medicinal Properties
- (2015) Alexei Kharitonenkov et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- Triglycerides on the rise: should we swap seats on the seesaw?
- (2014) Peter Libby EUROPEAN HEART JOURNAL
- Triglycerides and cardiovascular disease
- (2014) Børge G Nordestgaard et al. LANCET
- Loss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease
- (2014) Anders Berg Jørgensen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Loss-of-Function Mutations in APOC3, Triglycerides, and Coronary Disease
- (2014) NEW ENGLAND JOURNAL OF MEDICINE
- Treatment potential for dyslipidaemia management in patients with coronary heart disease across Europe: Findings from the EUROASPIRE III survey
- (2013) Željko Reiner et al. ATHEROSCLEROSIS
- Selective peroxisome proliferator-activated receptorα modulators (SPPARMα): The next generation of peroxisome proliferator-activated receptor α-agonists
- (2013) Jean-Charles Fruchart Cardiovascular Diabetology
- Association Between Plasma Triglycerides and High-Density Lipoprotein Cholesterol and Microvascular Kidney Disease and Retinopathy in Type 2 Diabetes Mellitus
- (2013) Frank M. Sacks et al. CIRCULATION
- HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment
- (2013) et al. EUROPEAN HEART JOURNAL
- Remnant cholesterol as a cause of ischemic heart disease: Evidence, definition, measurement, atherogenicity, high risk patients, and present and future treatment
- (2013) Anette Varbo et al. PHARMACOLOGY & THERAPEUTICS
- Reversibility of Fenofibrate Therapy-Induced Renal Function Impairment in ACCORD Type 2 Diabetic Participants
- (2012) J. C. Mychaleckyj et al. DIABETES CARE
- Statins suppress apolipoprotein CIII-induced vascular endothelial cell activation and monocyte adhesion
- (2012) Chunyu Zheng et al. EUROPEAN HEART JOURNAL
- Prevalence of lipid abnormalities in the United States: The National Health and Nutrition Examination Survey 2003–2006
- (2012) Peter P. Tóth et al. Journal of Clinical Lipidology
- Remnant Cholesterol as a Causal Risk Factor for Ischemic Heart Disease
- (2012) Anette Varbo et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study
- (2012) Benjamin F Voight et al. LANCET
- Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome
- (2012) Gregory G. Schwartz et al. NEW ENGLAND JOURNAL OF MEDICINE
- PPARs at the crossroads of lipid signaling and inflammation
- (2012) Walter Wahli et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- Apolipoprotein A-V; a potent triglyceride reducer
- (2011) Stefan K. Nilsson et al. ATHEROSCLEROSIS
- Triglycerides and Cardiovascular Disease
- (2011) Michael Miller et al. CIRCULATION
- Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management
- (2011) M. John Chapman et al. EUROPEAN HEART JOURNAL
- Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
- (2011) NEW ENGLAND JOURNAL OF MEDICINE
- Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study
- (2010) T. M. E. Davis et al. DIABETOLOGIA
- Combination Lipid Therapy in Type 2 Diabetes
- (2010) NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Medical Therapies on Retinopathy Progression in Type 2 Diabetes
- (2010) NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
- (2010) NEW ENGLAND JOURNAL OF MEDICINE
- Plasma Triglycerides and Cardiovascular Events in the Treating to New Targets and Incremental Decrease in End-Points Through Aggressive Lipid Lowering Trials of Statins in Patients With Coronary Artery Disease
- (2009) Ole Faergeman et al. AMERICAN JOURNAL OF CARDIOLOGY
- Peroxisome proliferator-activated receptor-alpha (PPARα): At the crossroads of obesity, diabetes and cardiovascular disease
- (2009) Jean-Charles Fruchart ATHEROSCLEROSIS
- Major Lipids, Apolipoproteins, and Risk of Vascular Disease
- (2009) The Emerging Risk Factors Collaboration* JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- The Residual Risk Reduction Initiative: A Call to Action to Reduce Residual Vascular Risk in Patients with Dyslipidemia
- (2008) Jean-Charles Fruchart et al. AMERICAN JOURNAL OF CARDIOLOGY
- Lipids, Apolipoproteins, and Their Ratios in Relation to Cardiovascular Events With Statin Treatment
- (2008) John J.P. Kastelein et al. CIRCULATION
- Impact of Triglyceride Levels Beyond Low-Density Lipoprotein Cholesterol After Acute Coronary Syndrome in the PROVE IT-TIMI 22 Trial
- (2008) Michael Miller et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Fibrates and future PPARα agonists in the treatment of cardiovascular disease
- (2008) Bart Staels et al. Nature clinical practice. Cardiovascular medicine
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started